Your browser doesn't support javascript.
loading
Case report: Rapid improvements of anorexia nervosa and probable myalgic encephalomyelitis/chronic fatigue syndrome upon metreleptin treatment during two dosing episodes.
Hebebrand, Johannes; Antel, Jochen; von Piechowski, Linda; Kiewert, Cordula; Stüve, Burkhard; Gradl-Dietsch, Gertraud.
Affiliation
  • Hebebrand J; Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Antel J; Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • von Piechowski L; Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Münster, University of Münster, Münster, Germany.
  • Kiewert C; Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Stüve B; Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Gradl-Dietsch G; Department of Neuropediatrics, DRK Children's Hospital, Siegen, Germany.
Front Psychiatry ; 14: 1267495, 2023.
Article in En | MEDLINE | ID: mdl-38025476
ABSTRACT
A comorbidity of anorexia nervosa (AN) and myalgic encephalomyelitis (ME/CSF) is uncommon. A 17 years-old male adolescent with possible onset of ME/CFS after an Epstein Barr Virus infection (EBV) and later onset of AN during a second period of weight loss was twice treated off-label with metreleptin for 15 and 11 days, respectively. As in previous cases, eating disorder specific cognitions and mood improved. Interestingly, fatigue and post-exertional muscle pain (P-EMP) improved, too. We discuss potential mechanisms. Treatment with metreleptin may prove beneficial in AN and in ME/CSF associated with substantial weight loss.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Psychiatry Year: 2023 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Psychiatry Year: 2023 Document type: Article Affiliation country: Alemania